It depends on your health goal, your body's current oxidative load, and the quality of the supplement you choose
Abstract We conducted a disproportionality analysis of the FDA Adverse Event Reporting System (FAERS) database (2005 Q22024 Q3) to evaluate neurological adverse events (NAEs) associated with six glucagon-like peptide-1 receptor agonists (GLP-1 RAs): exenatide, liraglutide, lixisenatide, dulaglutide, semaglutide, and tirzepatide
Increased glycosaminoglycan synthesis : Reviewed in Pickart & Margolina 2018, supporting structural hydration capacity
The vote came despite a highly critical review of the peptide from FDAs staff scientists, who said there was little data suggesting BPC-157 is effective for medical use
But how would you comment on the general state of the science
Patients not currently on a GLP-1 medication begin at Tier 1, titrating up each month